Delhi Cabinet today cleared the business model for the state-of-the-art Institute of Liver and Biliary Sciences (ILBS) being set up in the capital.
The model approved by the Cabinet at its meeting chaired by Chief Minister Sheila Dikshit would enable the institute to be self-sufficient in nine years' time, an official spokesman said.
Advertisement
The capital cost and the finances for procuring medical equipment would be borne by Delhi Government.
The running cost would be given as grant-in-aid annually for the first few years.
Patients would not have to pay for diagnosis and treatment, but they will be charged for medicines and consumables.
The consultation charges for private patients would be Rs 400 and for semi-private patients Rs 200, while poor patients would be charged only Rs 10.
The salary structure of the ILBS would be comparable to AIIMS.
Source: PTI News
Patients would not have to pay for diagnosis and treatment, but they will be charged for medicines and consumables.
The consultation charges for private patients would be Rs 400 and for semi-private patients Rs 200, while poor patients would be charged only Rs 10.
The salary structure of the ILBS would be comparable to AIIMS.
Source: PTI News
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Corporate News
The first World Health Organisation (WHO)/ International Labour Organisation (ILO) joint global monitoring report shows that more action is needed to ensure healthier, safer, more resilient, and more social workplaces.
Successful career transitions could be possible when people leverage their existing skills in the new occupation. A new Artificial Intelligence tool helps employees figure out the right job according to their current skill set.
AI and big data rule the pharmaceutical sector by enhancing the drug development process and increasing the marketing and sales of drugs
Insurance companies in the US are working towards adding food to their coverage menu to improve the people's health under their coverage and cut hospital costs.
Pharmaceutical companies need to make strategic decisions that will provide financial benefit while showing strong commitment to global health and their patients during the pandemic.
